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Abstract: Ancient Egyptians smeared a mixture of dark soil on their eyelids and believed it protected
eyes from unknown forces (illness). Recent studies have proven that the dark soil across the Nile River
is rich in natural compounds including lead sulfide, which in low levels, promotes the production of
nitric oxide (240-fold) by keratinocytes, with strong immune stimulatory and antimicrobial properties.
Current investigations reveal anti-inflammatory and anti-infectious activities—including cytokines
and chemokines—in saliva, as well as its friendly microbiota, which lines the surface of the oral cavity,
its protection against inflammatory and infectious organisms in the stoma and other organs, such as
the cardiovascular and central nervous systems. In fact, saliva may soon become a safe and practical
surrogate biomarker for genomic/proteomic evaluations and to replace painful blood drawing and
its side effects. Another example is leprosy, or Hansen’s disease, a chronic inflammatory syndrome
and neglected tropical disease, which affects the skin, and peripheral and trigeminal neurons causing
a lack of sensation to heat and cold and loss of extremities. Leprosy has horrified humans for over
2000 years, as lepers were considered unclean sinners and were subsequently drawn out of towns.
This communication scrutinizes the past and the present state of saliva and leprosy to encounter
possible mystery and/or wisdom in ancient healing as the mixture of “sputum and dirt” as reported
in the biblical time.
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1. Introduction and Conclusion
Cleopatra’s darkened eyelids and eyebrows were primarily to protect her eyes from desert
sunburn and common infections than being exclusively used as cosmetics. As the dark Egyptian
soil across the Nile River is reported to be rich in natural compounds and minerals, in addition to
Galena and lead sulfide (PbS) [1,2]. Though in high doses, lead is toxic, in low levels it can: Promote
the production of nitric oxide, about 240-fold, by skin cells (keratinocytes); present anti-microbial
properties to activate macrophages; increase blood flow; and provoke immune responses in order to
fend off infections. Ancient Egyptians smeared a mixture of dark soil and plants called “kohl” on their
eyelids, believing that it would protect their eyes from unknown forces and illnesses (like infections
and conjunctivitis). “Indeed, this seemingly basic beauty product could have been one of the most
archaic ophthalmological preparations ever known by man” [3,4].
Recent studies reveal that the anti-inflammatory and anti-infectious activities in saliva could
protect the oral cavity from inflammatory and infectious agents [5–7]. In addition, the friendly
microbiota, which lines the surface of the mucosal cavity, counter infectious organisms from seeding in
the stoma and other organs, such as the cardiovascular and even the central nervous system. Besides,
the powerful cytokines/chemokines, with anti-inflammatory mediators and anti-infectious activity
in the saliva, can protect body entrance, which is open to all sorts of nutrients, as well as toxins and
infectious agents [8–10]. In fact, salvia may soon become a safe and a practical surrogate biomarker for
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genomic/proteomic evaluations, as well as replacing painful blood drawing procedures for routine
and reliable analysis with no possible transmission of blood-borne diseases, such as HIV/AID and viral
hepatitis when used for diagnostic purposes. Additionally, saliva is being increasingly acknowledged
as having diagnostic values with regard to genetic biomarkers [11]. A recent pilot clinical trial explored
huntingtin protein in saliva as a safe and non-invasive tool to diagnose Huntington disease in patients
with the early stage of the disease [12].
As in the biblical story, Jesus of Nazareth in the land of Egypt “spitted on the ground” and made
a paste to cover the eyes of a blind man who possibly had infected and swollen eyes, covered with
inflammation, and pus of germs. Indeed, this may support and explain that Jesus, a healer of his time,
had knowledge of infectious and inflammatory diseases and a possible cure for such.
Another example is leprosy, or Hansen’s disease, a chronic inflammatory syndrome and neglected
tropical disease, caused by slow-growing Gram-positive bacillus Mycobacterium leprae, which was
discovered by Armauer Hansen, MD (1873) from his patient with lesions. Leprosy is transmitted
possibly through cough, sneeze and open wounds and prolonged contact with a patient. Leprosy
affects the skin and peripheral and trigeminal neurons, which results in a lack of sensation to heat and
cold, and the loss of extremities. Eye complications include keratitis, corneal ulceration, conjunctivitis,
cataract and blindness [13]. The weakness of the eyelids, and the lack of the lid’s proper closure
to protect the eyes, can eventually lead to blindness. The World Health Organization (WHO) has
classified leprosy according to the number of skin injuries, and when six lesions or more are present it
is called multibacillary. Otherwise, it is called paucibacillary if the patient suffers from five or fewer
lesions [14]. Patients with exaggerated immune response who develop paucibacillary leprosy are
mostly non-infectious, but those with a low immune response develop multibacillary leprosy with
multiple lesions, which can become infectious. Overall, lepers have a dry mouth, low saliva, and a
loss of function in the soft and hard palate tissues, resulting in periodontitis and loss of teeth [15].
Most patients with lesions in the oral cavity are affected with the multibacillary form. Leprosy has
horrified humans throughout the ages from biblical times (>2000 years) where lepers were considered
as unclean sinners and drawn out of towns. Indeed, the chance to become infected with bacillus
is extremely low, as only 5% of the global population is susceptible to M. leprae [14]. According to
the Center for Disease Control and Prevention (CDC), about 150 people in the U.S.A, mostly in the
Southern States, are diagnosed with leprosy each year [16]. The rate is highest especially in India
(58%), Brazil (16%), South East Asia and Africa. The WHO reports a total of 200,000 people are infected
globally each year [14]. Armadillos are the only non-human animals found to be infectious in nature
and serve as a source of infection, specifically in the Southern States [16]. In addition, asymptomatic
carriers may release bacilli from the nasal cavity to contaminate the surrounding milieu, and M. leprae
has been isolated from the soil.
The last time a lepers’ colony existed in the mainland U.S.A, was in the Leper Home in Louisiana,
established in 1894 and renamed the National Leprosarium in Carville in 1917, which located between
Baton Rouge and New Orleans. Indeed, the lepers’ colony served as an educational source for infectious
diseases students and residents, with profound, unforgettable and lasting effects on those who had
visited (author’s personal experience, over 4 decades ago). It closed in 1999 due to the lack of funding
and later transformed into a historical museum for leprosy. Currently, the outpatient leprosy clinic is
operating in Baton Rouge, L.A. At present, there is only one Leper’s colony left in the U.S.A, Kalaupapa
in Hawaii, on the island of Molokai, with six elderly residents who have voluntarily stayed behind
due to major deformations and fear of rejection by society. Children with leprosy exhibit significant
decreases in the salivary total antioxidant capacity compared to healthy controls (p < 0.001) [17]. In the
early stages of the disease, multi-antibiotic therapy (rifampicin, dapsone and clofazimine), which has
been used since 1982, can cure patients [14]. Although therapy is proven to protect and be effective
when prescribed before nerve injuries, if not treated, then the symptoms will advance to deformation
and loss of extremities, such as the fingers, toes, nose, ears and lips, as well as blindness, with the
possibility of irreversible damage. The patients, who suffer from exaggerated hyperactive immune
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responses, which are generated against very low numbers of bacterial loads, can create an impotent
confounding factor for the management and treatment of leprosy [18]. Yet, Jesus had no fear to be
near the lepers, nor to speak or touch them or being touched by lepers. It was not until the last
century when early clinical studies (1922) showed spontaneous inactivation or self-healing in some
leper populations, specifically children, who were followed up less than one year [19]. Subsequent
trials lasting for over 25 years confirmed that some pediatric populations developed only minor or no
symptoms. Even some patients with early lesions of leprosy may experience their infection become
stabilized, or even experience their lesions disappear entirely due to effective immune responses,
which trigger self-healing [20,21]. In South India, 11% of those with paucibacillary [22] and 78% of
infected children from Culion Island in the Philippines [23] showed self-recovery, thus demonstrating
that leprosy is not a highly contagious disease. These findings further proved that leprosy occurs
only in a limited number of people, possibly in those with immunity predisposed to the disease. It is
hypothesized that the hypothiocyanite anion, with antimicrobial oxidizing effects, present in the lower
airways in the lungs, may protect against infection; while a lack of the agent in nasal and the orbital
cavity may increase susceptibility to infection with M. leprae bacilli [18]. After over two millennia, still
the mystery of leprosy has not been fully solved; yet unfortunate Hansen’s disease patients now are
not recognized as sinful and not forced out of society, nor scared off to the margin of the towns in the
fear of spreading the horrifying and disfiguring malady.
In conclusion, this communication overview explores the past and the present state of saliva and
leprosy to encounter possible mystery and/or wisdom in the ancient art of healing as in the mixture of
“sputum and dirt” as reported in biblical times.
2. Methods
Current search engines used for this investigation were: PubMed, Google Scholar, CDC,
WHO, Rare and neglected diseases, Medscape, Medline, MDLinx, Science and Nature magazines.
These databases were explored under one or combination of at least two keywords (saliva; leprosy;
Hansen’s disease; biomarkers; dirt; soil; Egypt, etc.). As an example, PubMed, the main search engine
source, was explored for keywords and a number of articles were detected as follows: Leprosy (27329),
leprosy and soil (70), saliva (33), paucibacillary leprosy (2006), multibacillary leprosy (2986), Egypt, soil,
eye (5) and ancient Egypt, black eye (4). A total of 190 related abstracts and 50 articles were carefully
scrutinized. Of those, 24 articles were found relevant to be used to prepare this communication.
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